New cancer drug XB371 enters human testing for advanced tumors
NCT ID NCT07123103
First seen Oct 31, 2025 · Last updated Jun 15, 2026 · Updated 34 times
Summary
This early-stage study tests a new drug, XB371, in about 150 people with advanced solid tumors that have come back or spread. The main goal is to check the drug's safety and find the best dose. Participants must be in fairly good health and have a life expectancy of at least 12 weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Exelixis Clinical Site #1
RECRUITINGSan Antonio, Texas, 78229, United States
-
Exelixis Clinical Site #2
RECRUITINGHuntersville, North Carolina, 28078, United States
-
Exelixis Clinical Site #3
RECRUITINGGrand Rapids, Michigan, 49546, United States
-
Exelixis Clinical Site #4
RECRUITINGOrlando, Florida, 32827, United States
-
Exelixis Clinical Site #5
RECRUITINGRogers, Arkansas, 72758, United States
-
Exelixis Clinical Site #6
RECRUITINGWashington D.C., District of Columbia, 20057, United States
-
Exelixis Clinical Site #7
RECRUITINGNew Brunswick, New Jersey, 08901, United States
-
Exelixis Clinical Site #8
RECRUITINGHouston, Texas, 77030, United States
-
Exelixis Clinical Site #9
RECRUITINGLos Angeles, California, 90033, United States
Conditions
Explore the condition pages connected to this study.